New insights into the correlations between circulating tumor cells and target organ metastasis

Scientists Discover That Special Immune Cells Stop Metastatic Cancer

Metastatic disease -- when cancer spreads from the primary tumor to other parts of the body -- is the cause of most cancer deaths. While researchers understand how cancer cells escape the primary site to seed new tumors, it's not well understood why some of these wayward cancer cells spawn new tumors -- sometimes decades later -- while others do not.

Now, a research team at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. The findings were published today in the journal Cell.

"Preventing or curing metastases is the most critical challenge in cancer," said study leader Julio Aguirre-Ghiso, Ph.D., director of MECCC's Cancer Dormancy Institute. "We think our findings have the potential to point to new therapies to prevent or treat metastatic disease." The study's co-first authors are Erica Dalla, Ph.D., a former student, and Michael Papanicolaou, Ph.D., a postdoctoral fellow in Dr. Aguirre-Ghiso's lab.

The Role of Dormancy in Cancer

Cells that migrate from primary tumors and seed metastatic tumors are called disseminated cancer cells (DCCs). Some DCCs behave aggressively, immediately starting tumors in new tissue, while others remain in a state of suspended animation referred to as dormancy.

"It's long been a mystery how some DCCs can remain in tissues for decades and never cause metastases, and we believe we've found the explanation," said Dr. Aguirre-Ghiso, who is also professor of cell biology, of oncology, and of medicine and the Rose C. Falkenstein Chair in Cancer Research at Albert Einstein College of Medicine.

Breast cancer and many other types of cancer metastasize to the lungs. In research involving three mouse models of metastatic breast cancer, Dr. Aguirre-Ghiso and colleagues determined that when breast cancer DCCs spread to the lung's air sacs (alveoli), they are kept in a dormant state by immune cells known as alveolar macrophages.

Insight into the Immune System

"Alveolar macrophages are the lung's first responders, defending the organ against bacteria and dangerous substances like environmental pollutants," said Dr. Aguirre-Ghiso. These specialized macrophages, he notes, appear early in embryonic development and reside within lung tissue for life.

"Our findings demonstrate a new role for these macrophages, in which they recognize DCCs and actively interact with them, and -- by secreting a protein called TGF-β2 -- produce signals in the cancer cells that keep them in a dormant state," Dr. Aguirre-Ghiso said. "Since every organ in the body has its own set of tissue-resident macrophages, they may function to keep DCCs in check in those organs as well. Our study has shown for the first time that these specialized macrophages function to actively induce dormancy in DCCs."

Confirming the importance of alveolar macrophages in keeping DCCs dormant, Dr. Aguirre-Ghiso and his team found that depleting them in the mice significantly increased the number of activated DCCs and subsequent metastases in their lungs compared to mice with normal levels of the immune cells.

As DCCs become more aggressive, the researchers found, they become resistant to the pro-dormancy signals produced by alveolar macrophages. Ultimately, this evasion mechanism enables some DCCs to "wake up" from dormancy and reactivate to form metastases.

"Understanding how immune cells keep DCCs in check could lead to new anti-metastatic cell therapies among other strategies," Dr. Aguirre-Ghiso said. For example, he noted, it may be possible to strengthen macrophage signaling so that DCCs never awaken from dormancy or find ways to prevent older DCCs from becoming resistant to dormancy signaling.

7 Cancer Drugs FDA Approved In September

Along with the premarket approval of Siemens' 3D breast-imaging technology, the FDA  approved seven oncology and hematology drugs in September. 

Here are seven oncology and hematology drugs approved by the FDA in September:

Selpercatinib for patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation.

Osimertinib for adult patients with locally advanced, unresectable (stage 3) non-small cell lung cancer with the following conditions:

Disease has not progressed from platinum-based chemoradiation therapy

Tumors have EGFR exon 19 deletions or exon 21 L858R mutations

Isatuximab-irfc, with bortezomib, lenalidomide and dexamethasone, for adults newly diagnosed with multiple myeloma and ineligible for autologous stem cell transplant

Amivantamab-vmjw, with carboplatin and pemetrexed, for adult patients with locally advanced or metastatic non-small cell lung cancer with the following conditions:

Epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations

Disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor

Embrolizumab, with pemetrexed and platinum chemotherapy, as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma

Ribociclib, with an aromatase inhibitor, for adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative stage 2 and 3 early breast cancer at high risk of recurrence.

The FDA also approved a ribociclib and letrozole co-pack for the same indication

Atezolizumab and hyaluronidase-tqjs for subcutaneous injection, for all adult indications, as the intravenous formulation of atezolizumab including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft part sarcoma.

Interstitial Lung Disease

Diseases, Conditions, Syndromes

In 2023, The European Alliance of Associations for Rheumatology(EULAR) updated its recommendations for the treatment of systemic sclerosis (SSc), with many new inclusions around manifestations such as skin fibrosis and interstitial ...

---